iohexol has been researched along with Carcinoma, Islet Cell in 1 studies
Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.
Carcinoma, Islet Cell: A primary malignant neoplasm of the pancreatic ISLET CELLS. Usually it involves the non-INSULIN-producing cell types, the PANCREATIC ALPHA CELLS and the pancreatic delta cells (SOMATOSTATIN-SECRETING CELLS) in GLUCAGONOMA and SOMATOSTATINOMA, respectively.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fuhrman, GM | 1 |
| Charnsangavej, C | 1 |
| Abbruzzese, JL | 1 |
| Cleary, KR | 1 |
| Martin, RG | 1 |
| Fenoglio, CJ | 1 |
| Evans, DB | 1 |
1 other study available for iohexol and Carcinoma, Islet Cell
| Article | Year |
|---|---|
Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms.
Topics: Adenocarcinoma; Carcinoma, Islet Cell; Evaluation Studies as Topic; Female; Humans; Iohexol; Male; M | 1994 |